April 13, 2021 – The U.S. FDA has given accelerated approval to Trodelvy® (sacituzumab govitecan-hziy), manufactured by Gilead, for a new indication to treat locally advanced or
April 13, 2021 - Global Reach Health, committed to giving back to the community and beyond, hosted a donation drive this past week, for necessary supplies needed in Guatemala.
April 7, 2021 – The U.S. FDA has granted full approval for Trodelvy® (sacituzumab govitecan-hziy), manufactured by Gilead, to treat unresectable locally
April 6, 2021 – The U.S. FDA has approved a new dosing regimen for Erbitux® (cetuximab), manufactured by ImClone. The drug may now be administered once every two weeks to treat